Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Boehringer Ingelheim
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients who have been diagnosed with chronic obstructive pulmonary disease (chronic bronchitis, emphysema) by physician and need relief of various symptoms associated with Long Acting Beta2 Agonist (LABA) or Long Acting Muscarinic Antagonist (LAMA).
Patients who are prescribed Tio+Olo FDC 5µg/5µg for the first time
You may not be if
Patients who have been registered once in this study (i.e., re-entry of patients is not allowed).
Patients who are participating in a registry or clinical trial.
Patients who have a contraindication to Tio+Olo FDC 5µg/5µg defined in the package insert for Tio+Olo FDC 5µg/5µg.
Clareo Health | Long-term Use of Spiolto Respimat in Japanese Patients With Chronic Obstructive Pulmonary Disease
